Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6208 in advanced solid tumors
NCT06727812Phase 1Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-6208 in solid tumor, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Adverse Events, Maximum Tolerated Dose at 21 days and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
HRS-6208
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06727812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727812.